Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
35
pubmed:dateCreated
1995-10-4
pubmed:abstractText
Novel (Rp)-cAMPS analogs differed widely in ability to antagonize cAMP activation of pure cAMP-dependent protein kinase I and II and to antagonize actions of cAMP on gene expression, shape change, apoptosis, DNA replication, and protein phosphorylation in intact cells. These differences were related to different abilities of the analogs to stabilize the holoenzyme form relative to the dissociated form of cAMP kinase type I and II. (Rp)-8-Br-cAMPS and (Rp)-8-Cl-cAMPS were the most potent cAMP antagonists for isolated type I kinase and for cells expressing mostly type I kinase, like IPC-81 leukemia cells, fibroblasts transfected with type I regulatory subunit (RI), and primary hepatocytes. It is proposed that (Rp)-8-Br-cAMPS or (Rp)-8-Cl-cAMPS should replace (Rp)-cAMPS as the first line cAMP antagonist, particularly for studies in cells expressing predominantly type I kinase. The phosphorylation of endogenous hepatocyte proteins was affected oppositely by (Rp)-8-Br-cAMPS and increased cAMP, indicating that (Rp)-8-Br-cAMPS inhibited basal cAMP-kinase activity. The inhibition of basal kinase activity was accompanied by enhanced DNA replication, an effect which could be reproduced by microinjected mutant cAMP-subresponsive RI. It is concluded that the basal cAMP-kinase activity exerts a tonic inhibition of hepatocyte replication. (Rp)-8-Br-cAMPS and microinjected RI also desensitized hepatocytes toward inhibition of DNA synthesis by interleukin-1 beta. This indicates that basal cAMP-kinase activity can have a permissive role for the action of another (interleukin-1 beta) signaling pathway.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0021-9258
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
270
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
20599-607
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:7657638-3T3 Cells, pubmed-meshheading:7657638-Animals, pubmed-meshheading:7657638-Binding, Competitive, pubmed-meshheading:7657638-Binding Sites, pubmed-meshheading:7657638-Cell Line, Transformed, pubmed-meshheading:7657638-Cells, Cultured, pubmed-meshheading:7657638-Cyclic AMP, pubmed-meshheading:7657638-Cyclic AMP-Dependent Protein Kinases, pubmed-meshheading:7657638-Forskolin, pubmed-meshheading:7657638-Genes, ras, pubmed-meshheading:7657638-Humans, pubmed-meshheading:7657638-Interleukin-1, pubmed-meshheading:7657638-Kinetics, pubmed-meshheading:7657638-Liver, pubmed-meshheading:7657638-Male, pubmed-meshheading:7657638-Mice, pubmed-meshheading:7657638-Rats, pubmed-meshheading:7657638-Rats, Wistar, pubmed-meshheading:7657638-Structure-Activity Relationship, pubmed-meshheading:7657638-Thionucleotides, pubmed-meshheading:7657638-Thymidine, pubmed-meshheading:7657638-Tumor Cells, Cultured
pubmed:year
1995
pubmed:articleTitle
Novel (Rp)-cAMPS analogs as tools for inhibition of cAMP-kinase in cell culture. Basal cAMP-kinase activity modulates interleukin-1 beta action.
pubmed:affiliation
Department of Anatomy and Cell Biology, University of Bergen, Norway.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't